multiple sclerosis news from FierceBiotech
News
Merck Serono, Bionomics partner on MS programs
Merck Serono has signed up with Bionomics in a quest to develop new therapies for multiple sclerosis. Bionomics gains $2 million upfront, committed research funds and a partner who will pay up to $47 Read more...
Biovail focuses on CNS drugs
As the battle for Biovail continues, current CEO William Wells emphasized the company's focus on CNS drug development at Goldman Sachs' annual healthcare conference. Biovail is investing $600 million Read more...
ALSO NOTED: Acorda shares soar; Lexicon wins fast track; NIH grants $533N in research funds; and much more...
> News yesterday that Acorda Therapeutics' experimental MS drug helped patients walk better sent its shares up 27 percent. Read more...
SPOTLIGHT: Novartis touts new MS data
Researchers at Novartis say that after three years of therapy in an ongoing Phase II study, the oral FTY720 demonstrated positive results for patients with multiple sclerosis. Data demonstrate that Read more...
Eisai drug flunks Parkinson's trial
Eisai's has halted development of Perampanel (E2007) for Parkinson's after the drug failed a late-stage trial. Compared with placebo, E2007 didn't show a significant difference in the primary Read more...
Bad trial design faulted for GW's Phase III failure
Blindsided by a big placebo effect, GW Pharma says its lead therapy Sativex for pain narrowly missed hitting the goal of statistically Read more...
Q Therapeutics raises $15M
Salt Lake City-based Q Therapeutics has raised $15 million in a second round of financing. The company is developing cell-based therapies for the central nervous system. It is currently running Read more...
Lilly sees pipeline hope in MS drug
An article in the Indianapolis Star details Lilly's development program for MBP9289, a multiple sclerosis drug offering hope to both patients and a drug developer that hasn't launched a new drug for Read more...
Teva snaps up CoGenesys in $400M buyout
Teva has whetted at least part of its appetite for fresh acquisitions with the announcement this morning that it is buying CoGenesys for $400 million in cash. The Israeli generic drug company says Read more...
PeptImmune land $8.2M in series D
Cambridge, MA-based PeptImmune has garnered $8.2 million in a fourth round of funding. New Enterprise Associates, MPM Capital, Hunt Ventures L.P., Boston Medical Investors and Silicon Valley Bank Read more...
Get more multiple sclerosis coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends